基因组编辑：科技与全球市场

全球基因组编辑市场预计将从 2025 年的 108 亿美元成长到 2030 年底的 237 亿美元，预测期间（2025-2030 年）的复合年增长率为 16.9%。

从技术面来看，CRISPR-Cas 领域预计将从 2025 年的 78 亿美元成长到 2030 年底的 173 亿美元，预测期内复合年增长率为 17.4%。 TALEN 领域预计将从 2025 年的 13 亿美元成长到 2030 年底的 27 亿美元，预测期内复合年增长率为 15.6%。

本报告研究了全球基因组编辑市场，并提供了市场概况、市场影响因素和市场机会分析、市场规模趋势和预测以及各个细分市场和地区的详细分析。

目录

第一章执行摘要

• 市场展望
• 调查范围
• 市场摘要

第二章 市场概述

• 概述和市场定义
• 宏观经济因素
• 波特五力模型

第三章 市场动态

• 市场动态
• 市场驱动因素
• 遗传性疾病的盛行率
• 新的基因组编辑技术及应用
• 增加政府和私人资金
• 市场限制
• 政府政策法规
• 道德和社会问题
• 市场机会
• 拓展CRISPR技术的应用
• 在植物和牲畜育种的应用
• 市场挑战
• 基因编辑工作流程中的可扩展性限制
• CRISPR疗法的成本

第四章：监理现状

• 各国/地区监管情况
• 北美洲
• EU
• 亚太地区
• 其他地区

第五章 新兴技术与发展

• 新兴技术
• CRISPR的体内递送
• 改进的 Cas 变体
• AI
• 摘要：CRISPR 的新兴技术
• 临床试验分析
• 按研究类型进行的临床试验分析
• 临床试验分析：按状态
• 临床试验分析：按阶段
• 主要临床试验
• 摘要：临床试验概况
• 专利分析
• 专利：按年份
• 主要申请人的专利
• 专利：按主要专利拥有者
• 近期与基因组编辑技术相关的专利
• 智慧财产权纠纷及专利问题
• 关键重点：专利格局

第六章 市场区隔分析

• 细分市场
• 全球基因组编辑市场（按技术）
• CRISPR-Cas
• TALEN
• ZFN
• 其他基因组编辑平台
• 全球基因组编辑市场（按应用）
• 药物开发
• 植物育种
• 诊断
• 临床治疗
• 其他的
• 全球基因组编辑市场（按最终用户划分）
• 生物製药公司
• 农业生物技术
• 研究所
• 其他的
• 地理分布
• 全球基因组编辑市场（按地区）
• 北美洲
• 欧洲
• 亚太地区
• 其他地区

第七章 竞争讯息

• 市场排名分析
• 战略分析
• 最终摘要

第八章 基因组编辑市场的永续性：ESG 视角

• ESG：简介
• 基因组编辑的永续性：ESG 视角
• ESG议题
• ESG绩效分析
• 环境绩效
• 社会绩效
• 管治绩效
• BCC的结论

第九章 附录

• 调查方法
• 参考
• 简称
• 公司简介
• AGILENT TECHNOLOGIES INC.
• BEAM THERAPEUTICS
• CARIBOU BIOSCIENCES INC.
• CELLECTIS SA
• CRISPR THERAPEUTICS
• EDITAS MEDICINE
• GENSCRIPT
• INTELLIA THERAPEUTICS INC.
• MERCK KGAA
• ORIGENE TECHNOLOGIES INC.
• PRECISION BIOSCIENCES
• SANGAMO THERAPEUTICS
• TAKARA BIO INC.
• THERMO FISHER SCIENTIFIC INC.
• VERVE THERAPEUTICS INC.

The global market for genome editing is expected to grow from $10.8 billion in 2025 and is projected to reach $23.7 billion by the end of 2030, at a compound annual growth rate (CAGR) of 16.9% during the forecast period of 2025 to 2030.

The market for CRISPR-Cas genome editing technology is expected to grow from $7.8 billion in 2025 and is projected to reach $17.3 billion by the end of 2030, at a CAGR of 17.4% during the forecast period of 2025 to 2030.

The market for TALEN genome editing technology is expected to grow from $1.3 billion in 2025 and is projected to reach $2.7 billion by the end of 2030, at a CAGR of 15.6% during the forecast period of 2025 to 2030.

Report Scope

This report analyzes the market for genome editing technologies, applications and end users, offering insights into the market and technological trends. The study focuses on technologies such as CRISPR-Cas, transcription activator-like effector nucleases (TALEN) and zinc finger nucleases (ZFN), assessing their adoption in biopharmaceutical, agricultural biotech and research sectors. The market is segmented by applications into drug development, plant breeding, diagnostics and clinical therapy.

The report provides an analysis covering the regions of North America, Europe, Asia-Pacific and the Rest of the World (RoW), which includes Latin America, the Middle East and Africa. It evaluates the drivers, restraints, opportunities and challenges affecting the market and vendor landscape. It discusses clinical trials, patents and emerging technologies related to the market and looks at ESG-related developments.

The study offers an analysis of the competitive landscape, which ranks the top companies in the global market for genome editing. It also has a section with company profiles covering details of the market leaders. For market estimates, data has been provided for 2022 and 2023 as the historic years, 2024 as the base year, and forecasts for 2025 to 2030.

Report Includes

• 52 data tables and 58 additional tables
• A review of the global market for genome editing technologies
• Analyses of the global market trends, with market revenue data from 2022 to 2024, estimates for 2025, and projected CAGRs through 2030
• Evaluation and forecast of the genome editing market, and a corresponding market share analysis by product, application, end user and geographic region
• In-depth facts and figures concerning market drivers and deterrents, and other macroeconomic forces influencing the genome editing market
• A look at the use of clustered regularly interspaced short palindromic repeats (CRISPR)-Cas9, and how it has fueled the growth of the genome editing industry
• An evaluation of the recent technological breakthroughs and issues, market regulations, and the current status of the intellectual property rights of the CRISPR-Cas9 genome editing technology
• Review of patent trends and research publications in the global genome editing industry
• Insight into the industry structure, competitive landscape, R&D activity, growth strategies and ESG trends
• Identification of the companies best positioned to meet market demand due to their proprietary technologies, mergers and acquisitions, joint ventures and other strategic alliances
• Profiles of the leading companies, including Merck KGaA, Thermo Fisher Scientific, Beam Therapeutics, CRISPR Therapeutics, and Cellectis S.A.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary

Chapter 2 Market Overview

• Overview and Market Definition
• Macroeconomic Factors
• Porter's Five Forces Model
• Bargaining Power of Buyers
• Bargaining Power of Suppliers
• Potential for New Entrants
• Competition in the Industry
• Threat of Substitutes

Chapter 3 Market Dynamics

• Market Dynamics
• Market Drivers
• Prevalence of Genetic Disorders
• New Genome-Editing Technologies and Applications
• Increasing Government and Private Funding
• Market Restraints
• Governmental Policies and Regulations
• Ethical and Societal Concerns
• Market Opportunities
• Expanding Applications for CRISPR Technology
• Applications in Plant and Livestock Breeding
• Market Challenges
• Scalability Constraints in Gene Editing Workflows
• Cost of CRISPR-based Therapy

Chapter 4 Regulatory Landscape

• Regulatory Scenario, by Country/Region
• North America
• EU
• Asia-Pacific
• Rest of the World

Chapter 5 Emerging Technologies and Developments

• Emerging Technologies
• In Vivo Delivery of CRISPR
• Improved Cas Variants
• Artificial Intelligence
• Takeaways: Emerging Technologies in CRISPR
• Clinical Trials Analysis
• Clinical Trials Analysis, by Type of Study
• Clinical Trials Analysis, by Status
• Clinical Trials Analysis, by Phase
• Selected Clinical Trials
• Takeaways: Clinical Trials Landscape
• Patent Analysis
• Patents, by Year
• Patents, by Leading Applicant
• Patents, by Leading Patent Holder
• Recent Patents Relating to Genome Editing Technology
• IP Disputes and Patent Issues
• Key Takeaways: Patent Landscape (2020-2024)

Chapter 6 Market Segment Analysis

• Segmentation Breakdown
• Global Genome Editing Market, by Technology Type
• CRISPR-Cas
• TALEN
• ZFNs
• Other Genome Editing Platforms
• Global Genome Editing Market, by Application
• Drug Development
• Plant Breeding
• Diagnostics
• Clinical Therapy
• Other Applications
• Global Genome Editing Market, by End User
• Biopharmaceutical Companies
• Agricultural Biotechnology
• Research Institutions
• Other End Users
• Geographic Breakdown
• Global Genome Editing Market, by Region
• North America
• Europe
• Asia-Pacific
• Rest of the World

Chapter 7 Competitive Intelligence

• Market Ranking Analysis
• Strategic Analysis
• Final Takeaways

Chapter 8 Sustainability in the Genome Editing Market: ESG Perspective

• Introduction to ESG
• Sustainability in Genome Editing: An ESG Perspective
• ESG Issues
• ESG Performance Analysis
• Environmental Performance
• Social Performance
• Governance Performance
• Concluding Remarks from BCC

Chapter 9 Appendix

• Methodology
• References
• Abbreviations
• Company Profiles
• AGILENT TECHNOLOGIES INC.
• BEAM THERAPEUTICS
• CARIBOU BIOSCIENCES INC.
• CELLECTIS S.A.
• CRISPR THERAPEUTICS
• EDITAS MEDICINE
• GENSCRIPT
• INTELLIA THERAPEUTICS INC.
• MERCK KGAA
• ORIGENE TECHNOLOGIES INC.
• PRECISION BIOSCIENCES
• SANGAMO THERAPEUTICS
• TAKARA BIO INC.
• THERMO FISHER SCIENTIFIC INC.
• VERVE THERAPEUTICS INC.

List of Tables

• Summary Table : Global Market for Genome Editing, by Technology, Through 2030
• Table 1 : CRISPR-based Therapies for Genetic Diseases
• Table 2 : Asia-Pacific Regulatory Landscape
• Table 3 : RoW Regulatory Landscape
• Table 4 : Clinical Trials in CRISPR Technology, by Type of Study
• Table 5 : Clinical Trials for CRISPR Technology, by Status, as of August 2024
• Table 6 : Clinical Trials for CRISPR Technology, by Phase, as of August 2024
• Table 7 : Clinical Trials, 2024
• Table 8 : Most CRISPR Technology Patents, by Applicant, 2020-2024
• Table 9 : Leading Patent Holders for CRISPR Technology, by Number of Patents, 2020-2024
• Table 10 : Genome Editing Technology Patents Filed, 2024 and 2025
• Table 11 : Global Market for Genome Editing, by Technology, Through 2030
• Table 12 : Global Market for CRISPR-Cas Genome Editing Technology, by Region, Through 2030
• Table 13 : Global Market for TALEN Genome Editing Technology, by Region, Through 2030
• Table 14 : Global Market for ZFN Genome Editing Technology, by Region, Through 2030
• Table 15 : Global Market for Other Genome Editing Technologies, by Region, Through 2030
• Table 16 : Global Market for Genome Editing, by Application, Through 2030
• Table 17 : Global Market for Genome Editing in Drug Development, by Region, Through 2030
• Table 18 : Global Market for Genome Editing in Plant Breeding, by Region, Through 2030
• Table 19 : Global Market for Genome Editing in Diagnostics, by Region, Through 2030
• Table 20 : Global Market for Genome Editing in Clinical Therapy, by Region, Through 2030
• Table 21 : Global Market for Genome Editing in Other Applications, by Region, Through 2030
• Table 22 : Global Market for Genome Editing, by End User, Through 2030
• Table 23 : Global Market for Genome Editing for Biopharmaceuticals, by Region, Through 2030
• Table 24 : Global Market for Genome Editing for Agricultural Biotechnology, by Region, Through 2030
• Table 25 : Global Market for Genome Editing for Research Institutions, by Region, Through 2030
• Table 26 : Global Market for Genome Editing for Other End Users, by Region, Through 2030
• Table 27 : Global Market for Genome Editing, by Region, Through 2030
• Table 28 : North American Market for Genome Editing, by Country, Through 2030
• Table 29 : North American Market for Genome Editing, by Technology, Through 2030
• Table 30 : North American Market for Genome Editing, by Application, Through 2030
• Table 31 : North American Market for Genome Editing, by End User, Through 2030
• Table 32 : European Market for Genome Editing, by Country, Through 2030
• Table 33 : European Market for Genome Editing, by Technology, Through 2030
• Table 34 : European Market for Genome Editing, by Application, Through 2030
• Table 35 : European Market for Genome Editing, by End User, Through 2030
• Table 36 : Asia-Pacific Market for Genome Editing, by Country, Through 2030
• Table 37 : Asia-Pacific Market for Genome Editing, by Technology, Through 2030
• Table 38 : Asia-Pacific Market for Genome Editing, by Application, Through 2030
• Table 39 : Asia-Pacific Market for Genome Editing, by End User, Through 2030
• Table 40 : RoW Market for Genome Editing, by Technology, Through 2030
• Table 41 : RoW Market for Genome Editing, by Application, Through 2030
• Table 42 : RoW Market for Genome Editing, by End User, Through 2030
• Table 43 : Ranking of Genome Editing Companies
• Table 44 : CRISPR Technology Companies
• Table 45 : Recent Developments in the CRISPR Technology Industry, 2022-2025
• Table 46 : Bioethical Issues and Risks Associated with CRISPR Technology
• Table 47 : ESG Rankings for Genome Editing Companies, 2024*
• Table 48 : ESG: Environmental Overview
• Table 49 : ESG: Social Overview
• Table 50 : ESG: Governance Overview
• Table 51 : Information Sources for this Report
• Table 52 : Abbreviations Used in this Report
• Table 53 : Agilent Technologies Inc.: Company Snapshot
• Table 54 : Agilent Technologies Inc.: Financial Performance, FY 2023 and 2024
• Table 55 : Agilent Technologies Inc.: Product Portfolio
• Table 56 : Agilent Technologies Inc.: News/Key Developments, 2024
• Table 57 : Beam Therapeutics: Company Snapshot
• Table 58 : Beam Therapeutics: Financial Performance, FY 2023 and 2024
• Table 59 : Beam Therapeutics: Product Portfolio
• Table 60 : Beam Therapeutics: News/Key Developments, 2021-2023
• Table 61 : Caribou Biosciences Inc.: Company Snapshot
• Table 62 : Caribou Biosciences Inc.: Financial Performance, FY 2022 and 2023
• Table 63 : Caribou Biosciences Inc.: Product Portfolio
• Table 64 : Caribou Biosciences Inc.: News/Key Developments, 2021-2023
• Table 65 : Cellectis S.A.: Company Snapshot
• Table 66 : Cellectis S.A.: Financial Performance, FY 2023 and 2024
• Table 67 : Cellectis S.A.: Product Portfolio
• Table 68 : Cellectis S.A.: News/Key Developments, 2021-2024
• Table 69 : CRISPR Therapeutics: Company Snapshot
• Table 70 : CRISPR Therapeutics: Financial Performance, FY 2023 and 2024
• Table 71 : CRISPR Therapeutics: Product Portfolio
• Table 72 : CRISPR Therapeutics: News/Key Developments, 2021-2024
• Table 73 : Editas Medicine: Company Snapshot
• Table 74 : Editas Medicine: Financial Performance, FY 2023 and 2024
• Table 75 : Editas Medicine: Product Portfolio
• Table 76 : Editas Medicine: News/Key Developments, 2024 and 2025
• Table 77 : GenScript: Company Snapshot
• Table 78 : GenScript: Financial Performance, FY 2023 and 2024
• Table 79 : GenScript: Product Portfolio
• Table 80 : GenScript: News/Key Developments, 2022 and 2023
• Table 81 : Intellia Therapeutics Inc.: Company Snapshot
• Table 82 : Intellia Therapeutics Inc.: Financial Performance, FY 2023 and 2024
• Table 83 : Intellia Therapeutics Inc.: Product Portfolio
• Table 84 : Merck KGaA: Company Snapshot
• Table 85 : Merck KGaA: Financial Performance, FY 2023 and 2024
• Table 86 : Merck KGaA: Product Portfolio
• Table 87 : Merck KGaA: News/Key Developments, 2021 and 2024
• Table 88 : Origene Technologies Inc.: Company Snapshot
• Table 89 : Origene Technologies Inc.: Product Portfolio
• Table 90 : Precision BioSciences: Company Snapshot
• Table 91 : Precision BioSciences: Financial Performance, FY 2023 and 2024
• Table 92 : Precision BioSciences: Product Portfolio
• Table 93 : Precision BioSciences: News/Key Developments, 2022 and 2025
• Table 94 : Sangamo Therapeutics: Company Snapshot
• Table 95 : Sangamo Therapeutics: Financial Performance, FY 2023 and 2024
• Table 96 : Sangamo Therapeutics: Product Portfolio
• Table 97 : Sangamo Therapeutics: News/Key Developments, 2024
• Table 98 : Takara Bio Inc.: Company Snapshot
• Table 99 : Takara Bio Inc.: Financial Performance, FY 2023 and 2024
• Table 100 : Takara Bio Inc.: Product Portfolio
• Table 101 : Takara Bio Inc.: News/Key Developments, 2024
• Table 102 : Thermo Fisher Scientific Inc.: Company Snapshot
• Table 103 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2023 and 2024
• Table 104 : Thermo Fisher Scientific Inc: Product Portfolio
• Table 105 : Thermo Fisher Scientific Inc.: News/Key Developments, 2021 and 2022
• Table 106 : Verve Therapeutics Inc.: Company Snapshot
• Table 107 : Verve Therapeutics Inc.: Financial Performance, FY 2023 and 2024
• Table 108 : Verve Therapeutics Inc.: Product Portfolio
• Table 109 : Verve Therapeutics Inc.: News/Key Developments, 2024 and 2025

List of Figures

• Summary Figure : Global Market Shares of Genome Editing, by Technology, 2024
• Figure 1 : Porter's Five Forces Analysis for the Genome Editing Market
• Figure 2 : Market Dynamics Snapshot
• Figure 3 : Emerging Trends/Technologies in the CRISPR Market
• Figure 4 : Patents Granted Related to CRISPR Technology, by Year, 2020-2024
• Figure 5 : Global Market Shares of Genome Editing, by Technology, 2024
• Figure 6 : Workflow for CRISPR Gene Editing
• Figure 7 : Global Market Shares of Genome Editing, by Application, 2024
• Figure 8 : Global Market Shares of Genome Editing, by End User, 2024
• Figure 9 : Global Market Shares of Genome Editing, by Region, 2024
• Figure 10 : North American Market Shares of Genome Editing, by Country, 2024
• Figure 11 : European Market Shares of Genome Editing, by Country, 2024
• Figure 12 : Asia-Pacific Market Shares of Genome Editing, by Country, 2024
• Figure 13 : ESG Pillars
• Figure 14 : Advantages of ESG
• Figure 15 : Agilent Technologies Inc.: Revenue Shares, by Business Unit, FY 2024
• Figure 16 : Agilent Technologies Inc.: Revenue Shares, by Country/Region, FY 2024
• Figure 17 : GenScript: Revenue Shares, by Business Unit, FY 2024
• Figure 18 : GenScript: Revenue Shares, by Country/Region, FY 2024
• Figure 19 : Merck KGaA: Revenue Shares, by Business Unit, FY 2024
• Figure 20 : Merck KGaA: Revenue Shares, by Country/Region, FY 2024
• Figure 21 : Takara Bio Inc.: Revenue Shares, by Business Unit, FY 2024
• Figure 22 : Takara Bio Inc.: Revenue Shares, by Country/Region, FY 2024
• Figure 23 : Thermo Fisher Scientific Inc.: Revenue Shares, by Business Unit, FY 2024
• Figure 24 : Thermo Fisher Scientific Inc.: Revenue Shares, by Country/Region, FY 2024